HRAS - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
ANKRD11	ankyrin repeat domain containing 11
ANKRD16	ankyrin repeat domain 16
ANKRD23	ankyrin repeat domain 23
ANKRD34B	ankyrin repeat domain 34B
APBB1IP	amyloid beta precursor protein binding family B member 1 interacting protein	Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants
ARAF	A-Raf proto-oncogene, serine/threonine kinase	RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	ATP	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
ARFGAP1	ARF GTPase activating protein 1	XBP1(S) activates chaperone genes COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic Clathrin-mediated endocytosis
ARHGAP10	Rho GTPase activating protein 10	Regulation of PAK-2p34 activity by PS-GAP/RHG10 RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle
ARHGAP29	Rho GTPase activating protein 29	RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle
ARHGEF1	Rho guanine nucleotide exchange factor 1	NRAGE signals death through JNK G alpha (12/13) signalling events RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle
ARHGEF18	Rho/Rac guanine nucleotide exchange factor 18	NRAGE signals death through JNK TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G alpha (12/13) signalling events RHOA GTPase cycle RAC1 GTPase cycle
BCL2	BCL2 apoptosis regulator	Activation of BAD and translocation to mitochondria BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Interleukin-4 and Interleukin-13 signaling The NLRP1 inflammasome Estrogen-dependent gene expression Estrogen-dependent nuclear events downstream of ESR-membrane signaling NFE2L2 regulating tumorigenic genes Regulation of MITF-M-dependent genes involved in apoptosis	Ibuprofen Paclitaxel Docetaxel Rasagiline AN-9 Paclitaxel docosahexaenoic acid Apoptone Eribulin Dexibuprofen Venetoclax Obatoclax Navitoclax Terpinen-4-ol Oleandrin	Cervical cancer Kaposi's sarcoma Chronic lymphocytic leukemia (CLL) Gastric cancer Nasopharyngeal cancer Choriocarcinoma Small cell lung cancer
BLID	BH3-like motif containing, cell death inducer
BMPR1A	bone morphogenetic protein receptor type 1A	Signaling by BMP	Dibotermin alfa	Juvenile polyposis syndrome Hereditary mixed polyposis syndrome
BRAF	B-Raf proto-oncogene, serine/threonine kinase	Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib	Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer
BRAP	BRCA1 associated protein	RAF activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants
BUB1	BUB1 mitotic checkpoint serine/threonine kinase	Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion RHO GTPases Activate Formins Mitotic Prometaphase EML4 and NUDC in mitotic spindle formation
C6orf62	chromosome 6 open reading frame 62
CAV1	caveolin 1	Triglyceride catabolism eNOS activation NOSTRIN mediated eNOS trafficking Thyroxine biosynthesis Basigin interactions Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability RHOA GTPase cycle Extra-nuclear estrogen signaling RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RAC3 GTPase cycle RHOF GTPase cycle FOXO-mediated transcription of cell cycle genes RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways		Congenital generalized lipodystrophy (CGL)
CCL4	C-C motif chemokine ligand 4	Chemokine receptors bind chemokines G alpha (i) signalling events Interleukin-10 signaling

Search Results for: HRAS